jxf吉祥坊

现任公司副总经理

硕士研究生学历，高级工程师。1984 年 8 月至 1987 年 7 月担任北京农业工程大学助教；1987 年 9 月至 1990 年 7 月于华东理工大学就读；1990 年 8 月至 1993 年 9 月担任华东理工大学讲师；1993 年 10 月至 1997 年 5 月于新加坡国立大学就读；1997年 6 月至 2000 年 1 月担任浙江汉生制药有限公司（筹）副总经理；2000 年 1 月至 2002 年 3 月担任浙江汉生制药有限公司副总经理；2002 年 12 月至 2004 年 8 月担任东阳市日升昌生物技术有限公司副总经理；2003 年 2 月起兼任上海中医药大学中药研究所副教授；2004 年 9 月至 2018 年 11 月担任浙江日升昌药业有限公司董事、副总经理；2022年8月起兼任浙江广厦职业技术大学绿色智能制药产业学院教学委员会副主任。2018 年 12 月至今担任jxf吉祥坊医药董事、副总经理。

近五年发表SCI论文、中文核心期刊论文以及授权发明专利：

1.      Li, Chen; Cao, Xue-Wei; Zhao, Jian*; Wang, Fu-Jun*; Effective Therapeutic Drug Delivery by GALA3, an Endosomal Escape Peptide with Reduced Hydrophobicity., Journal of Membrane Biology, 2020, 253(2): 139-152.     

2.      Cao, Xue-Wei; Wang, Fu-Jun; Liew, Oi-Wah; Lu, Ye-Zhou; Zhao, Jian; Analysis of Triterpenoid Saponins Reveals Insights into Structural Features Associated with Potent Protein Drug Enhancement Effects., Molecular Pharmaceutics, 2020, 17(2): 683-694.     

3.      Bai, Xue-Di; Cao, Xue-Wei; Chen, Yi-Hui; Fu, Long-Yun; Zhao, Jian; Wang, Fu-Jun; Constructing a better binding peptide for drug delivery targeting the interleukin-4 receptor//dgsian.com/Incs/Ueditor/themes/default/images/spacer.gif, Journal of Drug Targeting, 2020, 28(9): 970-981.      

4.      Chen, Yihui; Li, Si; Zhao, Jian; Cao, Xuewei*; Wang, Fujun; Efficient drug delivery by novel cell-penetrating peptide derived from Midkine, with two heparin binding sites braced by a length-specific helix., Journal of Drug Targeting, 2021, 30(3): 326-333.     

5.      Pang, Guibin; Liu, Yun; Wang, Yangyun; Wang, Yong; Wang, Fujun; Zhao, Jian; Zhang, Leshuai W; Endotoxin contamination in ovalbumin as viewed from a nano-immunotherapy perspective., Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2021, 14(1): e1747.     

6.      Lei Jin; Zhao Jian; Long MengYiChen; Cao XueWei; Wang FuJun*; In addition to its endosomal escape effect, platycodin D also synergizes with ribosomal inactivation protein to induce apoptosis in hepatoma cells through AKT and MAPK signaling pathways., Chemico-Biological Interactions, 2022, 364(-): 110058.     

7.      Kang, Ji-Yue; Cao, Xue-Wei; Wang, Fu-Jun*; Zhao, Jian*; Raddeanin A synergistically enhances the anti-tumor effect of MAP30 in multiple ways, more than promoting endosomal escape, Toxicology and Applied Pharmacology, 2022, 449: 116139.     

8.      Ren, ZeFeng; Zhao, Jian*; Cao, XueWei*; Wang, FuJun*; Tandem fusion of albumin-binding domains promoted soluble expression and stability of recombinant trichosanthin in vitro and in vivo., Protein Expression and Purification, 2022, 200: 106147.     

9.      He, Min-Lin; Lei, Jin; Cao, Xue-Wei; Zhao, Jian; Wang, Fu-Jun; Screening and characterisation of a novel efficient tumour cell-targeting peptide derived from insulin-like growth factor binding proteins, Journal of Drug Targeting, 2023, 31(5): 500-510.     

10.    Wang, Wei; Cao, Xue-Wei; Wang, Fu-Jun*; Zhao, Jian*; Cytotoxic effects of recombinant proteins enhanced by momordin Ic are dependent on cholesterol and ganglioside GM1, Toxicon, 2023, 229: 107129.     

11.    Pang, Guibin; Wei, Siqi; Zhao, Jian*; Wang, Fu-Jun*; Improving nanochemoimmunotherapy efficacy by boosting "eat-me" signaling and downregulating "don't-eat-me" signaling with Ganoderma lucidum polysaccharide-based drug delivery, Journal of Materials Chemistry B, 2023, 11(48): 11562-11577.     

12.    Wu, Yi-Jie; Lei, Jin; Zhao, Jian; Cao, Xue-Wei; Wang, Fu-Jun; Design and characterization of a novel tumor-homing cell-penetrating peptide for drug delivery in TGFBR3 high-expressing tumors, Chemical Biology & Drug Design, 2023, 102(6): 1421-1434.     

13.    Pang, Guibin; Chen, Piao; Cao, Xuewei; Yu, Huan; Zhang, Leshuai W; Zhao, Jian*; Wang, Fu-Jun*; Improving combination cancer immunotherapy by manipulating dual immunomodulatory signals with enzyme-triggered, cell-penetrating peptide-mediated biomodulators, Biomater Sci, 2024, 12(-): 776-789.     

14.    Chen, Piao; Cao, Xue-Wei*; Dong, Jing-Wen; Zhao, Jian; Wang, Fu-Jun*; Saponin and Ribosome-Inactivating Protein Synergistically Trigger Lysosome-Dependent Apoptosis by Inhibiting Lysophagy: Potential to Become a New Antitumor Strategy, Molecular Pharmaceutics, 2024, 21(6): 2993-3005.     

15.    Su, Ruo-Long; Cao, Xue-Wei*; Zhao, Jian; Wang, Fu-Jun*; A high hydrophobic moment arginine-rich peptide screened by a machine learning algorithm enhanced ADC antitumor activity, Journal of Peptide Science, 2024, 30(12): e3628.     

16.    Lei, Jin; Cao, Xue-Wei; Li, Peng-Fei; Zhao, Jian*; Wang, Fu-Jun*; Platycodin D reduces PD-L1 levels by inhibiting LXR-β activity and combines with nintedanib to enhance the tumor-killing effect of T cells, FEBS LETTERS, 2024, 598(24): 3053-3070.

17.    郭利成; 曹雪玮; 傅龙云; 王富军; 赵健*; 一种用于药物蛋白亲和纯化和跨膜转运的双功能标签的开发, 中国生物工程杂志, 2020, 40(6): 40-52.

18.    尹晓梦; 曹雪玮; 王富军; 赵健*; 张惠展; 雷公藤红素与凋亡蛋白突变体通过强化Nur77 诱发凋亡通路发挥协同抗肿瘤作用, 生物技术通报, 2020, 36(7): 11-21.

19.    Fujun Wang (王富军); Jian Zhao (赵健); Xuewei Cao (曹雪玮); Longyun Fu (傅龙云); Taozhu Zhang (张涛铸); Hanwen Shan (单含文);Xuzhong Yang (杨旭中), Tumor Targeting Polypeptide and Method of Use Thereof, 授权公告日：2023-01-31, 美国专利号：US 11,566,045 B2

20.    王富军; 赵健; 曹雪玮; 傅龙云; 张涛铸; 单含文;杨旭中, 肿瘤靶向多肽、制备方法及其应用, 专利证书号：第6121154号，授权公告日：2023-07-07, 中国专利号：ZL 2021 1 0610291.6

21.    王富军; 赵健; 曹雪玮; 傅龙云; 张涛铸; 单含文;杨旭中, 肿瘤靶向多肽、制备方法及其应用, 专利证书号：第6218589号，授权公告日：2023-08-08, 中国专利号：ZL 2021 1 0609525.5

22.    王富军; 赵健; 曹雪玮; 傅龙云; 张涛铸; 单含文;杨旭中, 肿瘤靶向多肽、制备方法及其应用, 专利证书号：第6235361号，授权公告日：2023-08-15, 中国专利号：ZL 2021 1 0609521.7